Noticias y Actividades de Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals pertenece a Cyclo Therapeutics.

Cyclo Therapeutics es una empresa que cotiza bajo el símbolo de cotización CYTH (US).

Fusión, adquisición y financiación con participación de Cyclo Therapeutics.

• Cyclo Therapeutics ha Rafael Holdings adquirido (publicado el 28 de abril de 2025).

Ver el organigrama con sus 10 ejecutivos principales

Biografías más buscadas en Cornerstone Pharmaceuticals

• John Goldberg, Chief Executive Officer
• Patrick Wilmerding, Director
• Joseph Stern, Director

Crear su alerta
para seguir los movimientos de los ejecutivos en Cornerstone Pharmaceuticals.

Cyclo Therapeutics tiene 1.913 competidores entre los que se incluyen Sanofi (Francia), Eli Lilly (Estados Unidos) y Moderna (Estados Unidos).

Popular M&A news in Farmacia

• Contraline acaba de anunciar una recaudación de fondos de 93 millones de dólares. (publicado el 3 de junio de 2026).
• Hims & Hers ha Eucalyptus adquirido (publicado el 2 de junio de 2026).
• Apotex ha presentado su expediente de OPI. Su símbolo de cotización será TSX. (publicado el 2 de junio de 2026).

Otros contactos sugeridos en el sector Farmacia

• Joaquin Duato - Chief Executive Officer and Chairman of the Board en Johnson & Johnson
• Richard Saynor - Chief Executive Officer en Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board en Abbott

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de Cornerstone Pharmaceuticals

• UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
• Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer
• Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022
• Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE
• Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.
• Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
• Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.
• European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer
• Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer NYSE:RFL
• Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML) NYSE:RFL
• View more press releases Close

Redes sociales sobre Cornerstone Pharmaceuticals

• Cornerstone Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• Cornerstone Pharmaceuticals en LinkedIn, Twitter y YouTube